CytRx Corporation Reports Additional Analyses Supporting Highly Statistically Significant Positive Results From Global Phase 2b Clinical Trial With Aldoxorubicin In Advanced Soft Tissue Sarcomas

Published: Jan 08, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported positive results from additional statistical analyses that further support the previously announced highly positive top-line efficacy results from a multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS).

Help employers find you! Check out all the jobs and post your resume.

Back to news